Cantor Fitzgerald restated their hold rating on shares of Novavax (NASDAQ:NVAX) in a report published on Thursday. Cantor Fitzgerald currently has a $2.00 target price on the biopharmaceutical company’s stock.
“NanoFlu seasonal flu vaccine could be just what the Dr. ordered. The mismatch of commercially available (egg-production-based) seasonal flu vaccines in the current season underscores the theoretical utility of NVAX’s vaccine production technology. Avoiding influenza virus propagation in eggs could reduce the need for egg adaptation and possible generation of virus particles that do not faithfully resemble the wild type viruses recommended by health organizations for inclusion in flu vaccines. Particularly when prevailing strains are highly pathogenic, e.g., H3N2, having a better matched flu vaccine would seem to be desirable, in our view.”,” Cantor Fitzgerald’s analyst commented.
Other equities analysts have also recently issued research reports about the company. S&P Equity Research lowered their target price on Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. B. Riley set a $10.00 target price on Novavax and gave the company a buy rating in a research note on Thursday, March 1st. BidaskClub raised Novavax from a hold rating to a buy rating in a research note on Saturday, December 30th. Ladenburg Thalmann Financial Services lifted their target price on Novavax to $2.50 and gave the company a buy rating in a research note on Thursday, January 11th. Finally, Citigroup raised Novavax from a neutral rating to a buy rating in a research note on Thursday, March 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $3.11.
Shares of Novavax (NASDAQ NVAX) traded up $0.08 on Thursday, reaching $2.14. The company had a trading volume of 1,911,402 shares, compared to its average volume of 12,252,631. The stock has a market cap of $718.42, a PE ratio of -3.27 and a beta of 2.50. Novavax has a 1 year low of $0.73 and a 1 year high of $2.75. The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31.
Novavax (NASDAQ:NVAX) last released its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01). The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $7.98 million. During the same quarter in the previous year, the business posted ($0.21) earnings per share. Novavax’s quarterly revenue was up 92.6% on a year-over-year basis. equities analysts anticipate that Novavax will post -0.57 EPS for the current year.
Several institutional investors have recently made changes to their positions in NVAX. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Novavax by 49.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 29,800 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Novavax by 349.8% during the 4th quarter. Teacher Retirement System of Texas now owns 99,952 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 77,733 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of Novavax by 121.1% during the 4th quarter. Aperio Group LLC now owns 115,323 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 63,155 shares during the last quarter. Voya Investment Management LLC lifted its holdings in shares of Novavax by 18.6% during the 2nd quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 21,639 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Novavax during the 4th quarter valued at about $172,000. Institutional investors and hedge funds own 39.31% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/03/16/novavax-nvax-given-hold-rating-at-cantor-fitzgerald.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.